Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients.

[1]  J. Angel,et al.  CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  R. D. de Man,et al.  A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. , 2008, The Journal of infectious diseases.

[3]  L. Aurpibul,et al.  Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. , 2007, Vaccine.

[4]  A. Zanetti,et al.  Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. , 2007, Vaccine.

[5]  C. Mengoli,et al.  Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. , 2007, Vaccine.

[6]  M. Alter,et al.  A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States , 2006, Pediatrics.

[7]  G. Ruiz-Palacios,et al.  Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses , 2006, AIDS research and therapy.

[8]  Y. Chawla,et al.  Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine , 2006, BMC infectious diseases.

[9]  J. Laurence.  Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. , 2005, The American journal of medicine.

[10]  A. Barone,et al.  Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. , 2005, Vaccine.

[11]  A. Moorman,et al.  Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  I. D. de Messias-Reason,et al.  Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. , 2003, Vaccine.

[13]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[14]  J. Kahn.  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Lang,et al.  Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. , 2000, Vaccine.

[16]  P. van Damme,et al.  Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. , 1998, Vaccine.

[17]  A. Rosman,et al.  Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. , 1997, The American journal of medicine.

[18]  N. Principi,et al.  Impaired response to hepatitis B vaccine in HIV infected children. , 1992, Vaccine.

[19]  H. Handsfield,et al.  Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. , 1988, Annals of internal medicine.